Glenmark Pharmaceuticals gains on launching Tavulus for COPD treatment in Spain

11 Oct 2021 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 533.00, up by 6.20 points or 1.18 % from its previous closing of Rs. 526.80 on the BSE.

The scrip opened at Rs. 528.25 and has touched a high and low of Rs. 538.40 and Rs. 526.75 respectively. So far 62025 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 442.15 on 25-Mar-2021.

Last one week high and low of the scrip stood at Rs. 538.40 and Rs. 503.40 respectively. The current market cap of the company is Rs. 15151.02 crore.

The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 36.55% and 16.82% respectively.

Glenmark Pharmaceuticals has launched bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name ‘Tavulus’ in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).

Tavulus is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1992.70 -8.35 (-0.42%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×